
    
      This is a randomized, six-way crossover study to determine the efficacy and dose-response
      profile of SUN101. The study population will consist of subjects 40 to 65 years-old
      (inclusive), with a diagnosis of moderate to severe COPD. Aclidinium bromide 400 mcg bid will
      be given as an active comparator. The study will be double-blind for SUN-101 and placebo and
      will be open-label for aclidinium.
    
  